Study is the first to convincingly show the utility of parenchymal volume analysis in calculating split renal function in patients with renal masses considering radical nephrectomy.
Androgen-receptor (AR) antagonists can alter the metabolism of patients with prostate cancer, shows a recent study. And a transporter protein may become a new therapeutic target for kidney cancer.
This study establishes the volume-outcome association for metastatic renal cell carcinoma. High volume centers come out on top.
Patients with metastatic renal cell carcinoma respond better to combined atezolizumab and bevacizumab vs sunitinib alone. New biomarker data explain why.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Recruitment underway to bring additional leading scientists to expanding GU cancer research program at Cleveland Clinic.
This randomized phase 3 study compared treatment with sunitibib with a combination therapy of the anti-VEGF drug bevacizumab and atezolizumab, an engineered monoclonal antibody against PD-L1.
After partial nephrectomy, urologists find there’s still much follow-up work to do — from monitoring kidney function to cancer surveillance. What are the best methods for both?
Two studies show that a new combination immunotherapy regimen can produce remission in some patients and improve survival in metastatic melanoma and kidney cancer.
Accurate renal function measurement is critical to predict long-term adverse outcomes after nephrectomy. The relationship between chronic kidney disease and poor clinical outcomes is robust, but prediction can be improved by incorporating proteinuria.
Treatment gaps in renal cell cancer can compromise care. Knowing where they are is the first step toward addressing them; the next is to widen the use of evidence-based medicine.